2002
Potential Roles of Plasminogen Activator System in Coronary Vascular Remodeling Induced by Long-term Nitric Oxide Synthase Inhibition
Kaikita K, Schoenhard JA, Painter CA, Ripley RT, Brown NJ, Fogo AB, Vaughan DE. Potential Roles of Plasminogen Activator System in Coronary Vascular Remodeling Induced by Long-term Nitric Oxide Synthase Inhibition. Journal Of Molecular And Cellular Cardiology 2002, 34: 617-627. PMID: 12054849, DOI: 10.1006/jmcc.2002.2001.Peer-Reviewed Original ResearchConceptsSystolic blood pressureNitric oxide synthase inhibitionOxide synthase inhibitionPerivascular fibrosisBlood pressurePAI-1 deficiencyCoronary perivascular fibrosisPlasminogen activator systemL-NAMENOS inhibitionSynthase inhibitionDeficient miceVascular pathologyLong-term nitric oxide synthase inhibitionNitro-L-arginine methyl esterL-NAME-induced hypertensionLong-term NOS inhibitionPlasma TGF-beta1 levelsPlasminogen activator inhibitor-1-deficient miceStructural vascular changesTGF-beta1 levelsLong-term treatmentTissue-type plasminogen activator-deficient miceWeek study periodActivator system
1990
Octreotide: A Long-Acting Somatostatin Analog
Brown N, Johnston P, Arns P, Bluhm R, Branch R. Octreotide: A Long-Acting Somatostatin Analog. The American Journal Of The Medical Sciences 1990, 300: 267-273. PMID: 2248280, DOI: 10.1097/00000441-199010000-00011.Peer-Reviewed Original ResearchConceptsAcute treatmentSomatostatin analoguesGut neuroendocrine tumorsVasoactive intestinal peptideLong-term treatmentBlood sugar regulationNew therapeutic toolsCompassionate drug useCarcinoid syndromeTroublesome symptomsCarcinoid crisisGastrointestinal disordersIntestinal peptideNeuroendocrine tumorsDisease progressionNeuroendocrine disordersClinical informationSpecific indicationsClinical practiceDrug useTherapeutic toolLarger studyOctreotideLong-term studiesAdverse effects